Blood-brain barrier dysfunction as a potential therapeutic target for neurodegenerative disorders.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 487, doi. 10.1007/s12272-021-01332-8
- By:
- Publication type:
- Article
Works matching IS 02536269 AND DT 2021 AND VI 44 AND IP 5
Results: 6
1
2
COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 499, doi. 10.1007/s12272-021-01331-9
- By:
- Publication type:
- Article
3
Structural feature of TRAFs, their related human diseases and therapeutic intervention.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 475, doi. 10.1007/s12272-021-01330-w
- By:
- Publication type:
- Article
4
Ginkwanghols A and B, osteogenic coumaric acid-aliphatic alcohol hybrids from the leaves of Ginkgo biloba.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 514, doi. 10.1007/s12272-021-01329-3
- By:
- Publication type:
- Article
5
Phytochemistry and pharmacological activity of the genus artemisia.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 439, doi. 10.1007/s12272-021-01328-4
- By:
- Publication type:
- Article
6
Overexpressing microRNA-203 alleviates myocardial infarction via interacting with long non-coding RNA MIAT and mitochondrial coupling factor 6.
- Published in:
- Archives of Pharmacal Research, 2021, v. 44, n. 5, p. 525, doi. 10.1007/s12272-021-01324-8
- By:
- Publication type:
- Article